Literature DB >> 19723135

Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia.

D Marchaim1, K S Kaye, V G Fowler, D J Anderson, V Chawla, Y Golan, A W Karchmer, Y Carmeli.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is associated with increased mortality. Delay in appropriate antimicrobial therapy (DAAT) is an important risk factor for death, although confounding between carriage of MRSA and DAAT has not been resolved. We studied the association of risk factors with mortality and searched for specific populations vulnerable to DAAT. We conducted a case-control study comparing patients with MRSA bacteraemia who died during hospitalization (cases) with patients with MRSA bacteraemia who survived (controls) in three medical centres in two states. Patients were identified using computerized hospital databases for the years 2001-2005. Medical records were retrieved and various epidemiological data extracted. Bivariate and multivariate logistic regression analyses were performed. Overall, 388 patients with MRSA bacteraemia were included, 164 cases and 224 controls. According to bivariate analyses, cases were significantly more likely than controls to (i) be older (>65 years), (ii) have transferred from an institution, (iii) have stayed in an ICU, (iv) have had more invasive devices, (v) have a poorer prognosis on admission, (vi) have higher disease severity at the time of bacteraemia, and (vii) have a DAAT of > or = 2 days. Upon multivariate analysis, among patients >65 years, DAAT was significantly associated with increased mortality (p 0.04). Furthermore, patients >65 years with severe sepsis were much more likely to experience DAAT (p 0.02). In elderly patients with MRSA bacteraemia, DAAT is associated with increased mortality. Moreover, advanced age is a predictor for DAAT. These significant epidemiological associations mandate early coverage of MRSA in septic elderly patients.

Entities:  

Mesh:

Year:  2009        PMID: 19723135     DOI: 10.1111/j.1469-0691.2009.02934.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus.

Authors:  Nak-Hyun Kim; Hei Lim Koo; Pyoeng Gyun Choe; Pyeong Gyun Choe; Shinhye Cheon; Moonsuk Kim; Moon Suk Kim; Myung Jin Lee; Younghee Jung; Young Hee Jung; Wan Beom Park; Kyoung-Ho Song; Eu Suk Kim; Ji Hwan Bang; Hong Bin Kim; Sang Won Park; Nam Joong Kim; Myoung-don Oh; Eui Chong Kim
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

Review 2.  Predictors of mortality in Staphylococcus aureus Bacteremia.

Authors:  Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

3.  Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Tattevin; Brian S Schwartz; Christopher J Graber; Joann Volinski; Akta Bhukhen; Arti Bhukhen; Thuy T Mai; Nhung H Vo; Denise N Dang; Tiffany HaiVan Phan; Li Basuino; Françoise Perdreau-Remington; Henry F Chambers; Binh An Diep
Journal:  Clin Infect Dis       Date:  2012-06-05       Impact factor: 9.079

4.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.

Authors:  A J Kaasch; S Rieg; J Kuetscher; H-R Brodt; T Widmann; M Herrmann; C Meyer; T Welte; P Kern; U Haars; S Reuter; I Hübner; R Strauss; B Sinha; F M Brunkhorst; M Hellmich; G Fätkenheuer; W V Kern; H Seifert
Journal:  Infection       Date:  2013-03-29       Impact factor: 3.553

5.  Impact of a computerized alert system for bacteremia notification on the appropriate antibiotic treatment of Staphylococcus aureus bloodstream infections.

Authors:  J Kim; E-J Joo; Y E Ha; S Y Park; C-I Kang; D R Chung; J-H Song; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-30       Impact factor: 3.267

6.  Clinical predictors of methicillin-resistance and their impact on mortality associated with Staphylococcus aureus bacteraemia.

Authors:  Y M Wi; J Y Rhee; C I Kang; D R Chung; J H Song; K R Peck
Journal:  Epidemiol Infect       Date:  2018-05-21       Impact factor: 4.434

7.  Ten-year decrease of acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at a single institution: the result of a multifaceted program combining cross-transmission prevention and antimicrobial stewardship.

Authors:  Annie Chalfine; Marie-Dominique Kitzis; Yvonnick Bezie; Adel Benali; Laurence Perniceni; Jean-Claude Nguyen; Marie Françoise Dumay; Jacqueline Gonot; Gilles Rejasse; Fred Goldstein; Jean Carlet; Benoît Misset
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-18       Impact factor: 4.887

8.  Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants.

Authors:  Joshua T Thaden; Jessica E Ericson; Heather Cross; Stephen P Bergin; Julia A Messina; Vance G Fowler; Daniel K Benjamin; Reese H Clark; Christoph P Hornik; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2015-11       Impact factor: 3.806

9.  Antimicrobial Activity of a Novel Vascular Access Film Dressing Containing Chlorhexidine Gluconate.

Authors:  Anne Wibaux; Priyaleela Thota; Jozef Mastej; Daniel L Prince; Neal Carty; Peter Johnson
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

10.  Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Jonathan Seah; David C Lye; Tat-Ming Ng; Prabha Krishnan; Saugata Choudhury; Christine B Teng
Journal:  Virulence       Date:  2013-10-28       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.